Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

CBR1 Recombinant Antibody, Cy3 Conjugated

Product Specifications

Background

NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol.

Synonyms

15 hydroxyprostaglandin dehydrogenase [NADP+]; Carbonyl reductase [NADPH] 1; CBR1; CRN; NADPH dependent carbonyl reductase 1; Prostaglandin 9 ketoreductase; SDR21C1.

Gene ID

873

Swiss Prot

P16152

Cellular Locus

Cytoplasm

Host

Rabbit

Cross Reactivity

Human

Target

CBR1

Clonality

Recombinant

Isotype

IgG

Conjugation

Cy3

Source

KLH conjugated synthetic peptide derived from human CBR1

Applications

WB, IF

Purification

Purified by Protein A.

Excitation Emission

512,550nm/570,615nm

Concentration

Lot dependent

Dilution

WB (1:300-5000), IF ()

Buffer

Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Modification

Unmodified

Storage Conditions

Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Product Datasheet

https://www.biossantibodies.com/datasheets/bsm-61367R-Cy3

Gene ID URL

873

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

HIPK2 (NM_022740) Human Untagged Clone
SC311119 10 µg

HIPK2 (NM_022740) Human Untagged Clone

Ask
View Details
CCDC93 Mouse Monoclonal Antibody [Clone 1A10]
E45M14614V-2 50 µL

CCDC93 Mouse Monoclonal Antibody [Clone 1A10]

Ask
View Details
AT13148
B4158-10 10 mg

AT13148

Ask
View Details
TAS2R5 Antibody, HRP conjugated
A77203-100UL 100 µL

TAS2R5 Antibody, HRP conjugated

Ask
View Details
C1rL (h) -PR
sc-96010-PR 10 µM - 20 µL

C1rL (h) -PR

Ask
View Details